Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2009 2
2010 5
2011 2
2012 1
2013 1
2014 1
2015 4
2016 5
2017 2
2018 3
2019 6
2020 2
2021 2
2022 5
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab in Mild-to-Moderate Crohn's Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study.
Dotti AZ, Magro DO, Vilela EG, Chebli JMF, Chebli LA, Steinwurz F, Argollo M, Carvalho NS, Parente JML, Lima MM, Parra RS, Perin RL, Flores C, Morsoletto EM, da Costa Ferreira S, Ludvig JC, Kaiser Junior RL, Faria MAG, Nicollelli GM, Andrade AR, Queiroz NSF, Kotze PG. Dotti AZ, et al. Among authors: flores c. Crohns Colitis 360. 2023 Sep 22;5(4):otad053. doi: 10.1093/crocol/otad053. eCollection 2023 Oct. Crohns Colitis 360. 2023. PMID: 37859629 Free PMC article.
Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction-A Prospective Trial.
Garcia KS, de Azevedo MFC, Carlos AS, Barros LL, Oba J, Sobrado Junior CW, Sipahi AM, Alves ODC, Navarro-Rodriguez T, Parra RS, Chebli JMF, Chebli LA, Flores C, Vieira A, do Ceará CDA, Queiroz NSF, Damião AOMC. Garcia KS, et al. Among authors: flores c. Biomedicines. 2023 Jun 19;11(6):1757. doi: 10.3390/biomedicines11061757. Biomedicines. 2023. PMID: 37371853 Free PMC article.
SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF ULCERATIVE COLITIS IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).
Baima JP, Imbrizi M, Andrade AR, Chebli LA, Argollo MC, Queiroz NSF, Azevedo MFC, Vieira A, Costa MHM, Fróes RSB, Penna FGCE, Quaresma AB, Damião AOMC, Moraes ACDS, Santos CHMD, Flores C, Zaltman C, Vilela EG, Morsoletto E, Gonçalves Filho FA, Santana GO, Zabot GP, Parente JML, Sassaki LY, Zerôncio MA, Machado MB, Cassol OS, Kotze PG, Parra RS, Miszputen SJ, Coy CSR, Ambrogini Junior O, Chebli JMF, Saad-Hossne R. Baima JP, et al. Among authors: flores c. Arq Gastroenterol. 2023 Mar 24;59(suppl 1):51-84. doi: 10.1590/S0004-2803.2022005S1-03. eCollection 2023. Arq Gastroenterol. 2023. PMID: 36995889 Free article.
SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF CROHN'S DISEASE IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).
Imbrizi M, Baima JP, Azevedo MFC, Andrade AR, Queiroz NSF, Chebli JMF, Chebli LA, Argollo MC, Sassaki LY, Parra RS, Quaresma AB, Vieira A, Damião AOMC, Moraes ACDS, Flores C, Zaltman C, Vilela EG, Morsoletto EM, Gonçalves Filho FA, Penna FGCE, Santana GO, Zabot GP, Parente JML, Costa MHM, Zerôncio MA, Machado MB, Cassol OS, Kotze PG, Fróes RSB, Miszputen SJ, Ambrogini Junior O, Saad-Hossne R, Coy CSR. Imbrizi M, et al. Among authors: flores c. Arq Gastroenterol. 2023 Mar 24;59(suppl 1):20-50. doi: 10.1590/S0004-2803.2022005S1-02. eCollection 2023. Arq Gastroenterol. 2023. PMID: 36995888 Free article.
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study.
Perin RL, Magro DO, Andrade AR, Argollo M, Carvalho NS, Damião AOMC, Dotti AZ, Ferreira SDC, Flores C, Ludvig JC, Nones RB, Queiroz NSF, Parra RS, Steinwurz F, Teixeira FV, Kotze PG. Perin RL, et al. Among authors: flores c. Crohns Colitis 360. 2022 Dec 19;5(1):otac050. doi: 10.1093/crocol/otac050. eCollection 2023 Jan. Crohns Colitis 360. 2022. PMID: 36777366 Free PMC article.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
45 results